Clinical Trial Update: Daratumumab Combined With Bortezomib and Dexamethasone in Mayo 04 Stage III Light Chain Amyloidosis [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating daratumumab with bortezomib and dexamethasone for systemic light chain amyloidosis (AL) in Mayo 04 Stage III.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Light Chain Amyloidosis
• Systemic Amyloidosis

Drugs mentioned

• Bortezomib (bortezomib)
• DEXAMETHASONE (Dexamethasone)
• Daratumumab (daratumumab)

Snippet

Sponsor: Peking Union Medical College Hospital | Conditions: Amyloidosis; Systemic | Phase 2 | Status: UNKNOWN